Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?

被引：14
|
作者：
Yen, J. -H. [1 ]
机构：
[1] Kaohsiung Med Univ Hosp, Coll Med, Grad Inst Med, Dept Internal Med,Div Rheumatol, Kaohsiung 807, Taiwan
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2006年 / 60卷 / 10期
关键词：
rheumatoid arthritis; treatment; anti-rheumatic drugs;
D O I：
10.1016/j.biopha.2006.09.008
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Biologics are highly effective in the treatment of rheumatoid arthritis (RA), but they are very expensive. The costs of biologics should limit their usage in patients with RA, especially in the developing countries. Therefore, it is necessary to develop suitable strategies for treating RA patients in these countries. In this article, the efficacy, toxicity, and cost-effectiveness of conventional DMARDs and biologics will be investigated. The therapeutic strategies for treating early RA will also be proposed. (c) 2006 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：688 / 692
页数：5
相关论文
共 50 条
  • [1] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [2] Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
    Choy, Ernest H.
    [J]. RHEUMATOLOGY, 2019, 58 : 51 - 55
  • [3] Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries.
    Putrik, Polina
    Ramiro, Sofia
    Pavlova, Milena
    Kvien, Tore K.
    Sokka, Tuulikki
    Uhlig, Till
    Boonen, Annelies
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S784 - S784
  • [4] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [5] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [6] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [7] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    [J]. Clinical Rheumatology, 2020, 39 : 207 - 216
  • [8] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 148
  • [9] Use of Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in Quebec, Canada
    Roussy, Jean-Pascal
    Bessette, Louis
    Bernatsky, Sasha
    Rahme, Elham
    Legare, Jean
    Lachaine, Jean
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S855 - S855
  • [10] USE OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS IN QUEBEC, CANADA
    Roussy, J. P.
    Bessette, L.
    Bernatsky, S.
    Rahme, E.
    Legare, J.
    Lachaine, J.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A316 - A316
12345